The pleuromutilin antibiotic lefamulin demonstrated activity against the most relevant bacterial pathogens causing sexually transmitted infections (STI), including (MIC, 0.02/0.04 mg/liter; = 15), susceptible and multidrug-resistant (MIC range, 0.002 to 0.063 mg/liter; = 6), and susceptible and resistant (MIC, 0.12/0.5 mg/liter; = 25). The results suggest that lefamulin could be a promising first-line antibiotic for the treatment of STI, particularly in populations with high rates of resistance to standard-of-care antibiotics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923106 | PMC |
| http://dx.doi.org/10.1128/AAC.02380-17 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic Accuracy of Rapid Antigen Tests for Trichomoniasis: A Meta-analysis.
J Low Genit Tract Dis
January 2025
Department of Pathology, Saint Paul's Hospital, Taoyuan, Taiwan.
Objective: Trichomoniasis is a globally prevalent sexually transmitted infection caused by the protozoan Trichomonas vaginalis. Polymerase chain reaction (PCR) is the gold standard for diagnosing trichomoniasis, but it is expensive. Antigen tests are immunochromatographic immunoassays that detect T.
View Article and Find Full Text PDFDoxyPEP Implementation Preferences for Bacterial STD Prevention Among Gay, Bisexual, and Other Men Who Have Sex with Men Living With and Without HIV in Los Angeles: A Mixed-Methods Approach.
AIDS Patient Care STDS
January 2025
Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, California, USA.
Bacterial sexually transmitted diseases (STDs) remain prominent in the United States among gay, bisexual, and other men who have sex with men (GBMSM). Doxycycline for post-exposure prophylaxis (DoxyPEP) is a regimen by which the antibiotic doxycycline is taken after sex to prevent bacterial STDs, such as, chlamydia, gonorrhea, and syphilis. Despite this, this study was conducted because there are a limited number of publications that describe GBMSM's knowledge of, and interest in, taking DoxyPEP and preferences regarding its implementation.
View Article and Find Full Text PDFTSST-1 promotes colonization of within the vaginal tract by activation of CD8 T cells.
Infect Immun
January 2025
Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
Toxic shock syndrome toxin-1 (TSST-1) is a superantigen produced by and is the determinant of menstrual toxic shock syndrome (mTSS); however, the impact of TSST-1 on the vaginal environment beyond mTSS is not understood. Herein, we assessed how TSST-1 affects vaginal colonization by , host inflammatory responses, and changes in microbial communities within the murine vagina. We demonstrated that TSST-1 induced a CD8 T-cell-dependent inflammatory response in 24 h that correlated with persistence within the vaginal tract.
View Article and Find Full Text PDFMonkeypox-related knowledge and vaccination willingness among HIV-diagnosed and -suspected males: a cross-sectional survey in Changsha.
Front Public Health
January 2025
Changsha Centre for Disease Control and Prevention, Changsha, Hunan, China.
Objective: This study aimed to update baseline data on monkeypox (mpox)-related knowledge and vaccination willingness among human immunodeficiency virus (HIV) diagnosed and suspected males.
Methods: The cross-sectional survey was conducted in Changsha, a provincial capital in China, during 5 JULY to 5 SEPTEMBER 2023. Among the three study groups, the participants in the "previously diagnosed" group were recruited from a cohort of HIV-infected patients.
"If that would have lessened my symptoms, that would have been great...": a qualitative study about the acceptability of tecovirimat as treatment for mpox.
BMC Med
January 2025
Health Emergencies Programme, World Health Organization, Geneva, Switzerland.
Background: Tecovirimat, an antiviral treatment for smallpox, was approved as a treatment for mpox by the European Medicines Agency in January 2022. Approval was granted under "exceptional circumstances" based on effectiveness found in pre-clinical challenge studies in animals and safety studies in humans showing minimal side effects. As clinical efficacy studies are still ongoing, there is currently limited information with regard to the acceptability of tecovirimat to treat mpox.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!